feed,title,long_url,short_url
Benzinga,"Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows",https://benzinga.com/general/biotech/24/08/40102279/eli-lillys-popular-weight-lossdiabetes-drug-tirzepatide-cuts-heart-failure-risk-by-38-pivotal-pha,https://da.gd/n6ei
